SCHEMBL9616786

SCHEMBL9616786

COc1cc(/C=C/c2ccc(O)cc2)ccc1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.80
NFE2L2 Q16236 2/20 0.77
ABCB1 P08183 1/20 0.72
AKR1B1 P15121 1/20 0.72
MAOA P21397 1/20 0.72
MAOB P27338 1/20 0.72
APP P05067 5/20 0.72
MAPT P10636 1/20 0.72
TYR P14679 1/20 0.71
ALOX5 P09917 2/20 0.70
PTGS2 P35354 2/20 0.69
XDH P47989 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP2D6 P10635 1/20 0.65
NFKB1 P19838 1/20 0.65
HSD11B1 P28845 1/20 0.65
STAT3 P40763 1/20 0.65
NFKB2 Q00653 1/20 0.65
RELA Q04206 1/20 0.65
SNCA P37840 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5315843 1.00 TTR (0.80) TTRNFE2L2ABCB1AKR1B1MAOA
SCHEMBL671150 0.92 TTR (0.85) TTRNFE2L2ABCB1AKR1B1MAOA
SCHEMBL30807100 0.92 TTR (0.85) TTRNFE2L2ABCB1AKR1B1MAOA
SCHEMBL17732299 0.92 TTR (0.85) TTRNFE2L2ABCB1AKR1B1MAOA
SCHEMBL671149 0.92 TTR (0.85) TTRNFE2L2ABCB1AKR1B1MAOA
SCHEMBL14782177 0.89 TTR (1.00) TTRNFE2L2APPMAPTTYR
SCHEMBL3394333 0.89 TTR (0.93) TTRNFE2L2ABCB1AKR1B1MAOA
SCHEMBL13004148 0.89 TTR (1.00) TTRNFE2L2APPMAPTTYR
SCHEMBL2945375 0.87 NFE2L2 (0.75) TTRNFE2L2APPMAPTTYR
SCHEMBL4938984 0.87 NFE2L2 (0.75) TTRNFE2L2APPMAPTTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4202125-A None JP disclosed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US disclosed
US-10426742-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2019-10-01 US disclosed
US-20190022029-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2019-01-24 US disclosed
US-20160296477-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2016-10-13 US disclosed
WO-2013008175-A1 METHOD FOR PRODUCING TRANS-RESVERATROL AND THE ANALOGS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-01-17 WO disclosed
JP-H04202125-A MEDICINE FOR TREATING HEPATOPATHY TERUMO CORP 1992-07-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160296477-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB TTR 2988/4885NFE2L2 1303/4885ABCB1 2452/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 TTR 2045/4885NFE2L2 1941/4885ABCB1 1776/4885
US-10426742-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB TTR 2797/4885NFE2L2 1434/4885ABCB1 2309/4885
US-20190022029-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB TTR 2797/4885NFE2L2 1434/4885ABCB1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.